IBio Research and Development Expenses 2010-2024 | IBIO

IBio research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

IBio Research and Development Expenses 2010-2024 | IBIO

IBio research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$159.1B
Vertex Pharmaceuticals (VRTX)$124.6B
Bristol Myers Squibb (BMY)$118.6B
Gilead Sciences (GILD)$114.8B
CSL (CSLLY)$88.8B
Regeneron Pharmaceuticals (REGN)$86B
GSK (GSK)$71.3B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$33.3B
BioNTech SE (BNTX)$24.8B
Biogen (BIIB)$24B
Illumina (ILMN)$22.6B
BeiGene (BGNE)$18.8B
Moderna (MRNA)$15.3B
Incyte (INCY)$15B
Genmab (GMAB)$14B
Insmed (INSM)$12.7B
BioMarin Pharmaceutical (BMRN)$12.5B
Vaxcyte (PCVX)$11.6B
Bio-Techne Corp (TECH)$11.5B
Sarepta Therapeutics (SRPT)$10.4B
Exelixis (EXEL)$10B
Revolution Medicines (RVMD)$9.7B
QIAGEN (QGEN)$9.6B
Exact Sciences (EXAS)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Intra-Cellular Therapies (ITCI)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.5B